Transforming drug discovery on membrane proteins
Creoptix CEO Line S. Raquet and leadXpro CEO Michael Hennig look back on three years of partnership that transformed membrane protein drug discovery.
Stephan Müller
About Stephan Müller
Posts by Stephan Müller:
leadXpro produces protein for COVID-19 research campaign
leadXpro AG announces its involvement in a multiparty research collaboration by delivering SARS-CoV-2 M-glycoprotein, a promising therapeutic target against Covid-19.
leadXpro, first tenant of Park InnovAARE’s innovation campus
One month after the groundbreaking ceremony of Park Innovaare’s new Innovation Campus, leadXpro is the first company to sign a tenancy agreement.
leadXpro and Lundbeck partner for membrane protein structure research
Lundbeck partners with leadXpro to discover drugs for membrane protein targets by high-resolution X-ray and cryo-Electron Microscopy
leadXpro and Astex enter partnership on membrane protein structure research
Astex Pharmaceuticals partners with leadXpro to facilitate structure-based drug discovery for membrane protein targets by cryo-Electron Microscopy
leadXpro licenses cryoSPARC™ software
By licensing cryosparc software and upgrading of its in-house computing capacity, leadXpro enhances its ability for high resolution structure determination of membrane protein drug targets by single particle cryo-Electron Microscopy (cryo-EM)
Symposium on Drug Discovery @ SwissFEL
The registration for the International Symposium on Structure Biology for Drug Discovery@SwissFEL on June 25-27, 2019 in Villigen, Switzerland is now open.
Collaboration with Sanofi on cryo-EM based structure research
leadXpro and Sanofi collaborate for cryo-EM structure project
First biomolecular structure experiment at SwissFEL
leadXpro determined the first protein structure at the Swiss Free Electron Laser (SwissFEL) facilities.
Collaboration with the University of Zürich on membrane protein targeted sybodies
leadXpro AG and the University of Zurich (UZH) collaborate to generate sybodies as molecular discovery tools, therapeutic lead compounds and diagnostic reagents against disease-relevant membrane protein targets.